On 30 June 2025, Corporate Governance Asia presented the 15th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International Limited (“Fosun International”, “Fosun” or the “Group”) (HKEX stock code: 00656) were both honored Asia’s Best CEO. In addition, Fosun International was awarded Sustainable Asia Award 2025, Best Environmental Responsibility Award and Best Corporate Communications Award.

Henlius (2696.HK) announced that its self-developed anti-PD-1 monoclonal antibody (mAb) serplulimab (trade name in Europe: Hetronifly^®) has been approved in both the United Kingdom and India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Commercialisation in the UK and India will be led by Henlius’ partner Intas and its subsidiary Accord Healthcare.

TEL AVIV and SHANGHAI, June 16, 2025 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, SSE: 600196, HKEX: 02196) today announced that the companies, through their respective subsidiaries, have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. Teva’s internally developed ATTENUKINE technology provides a new mechanism of action, potentially offering high efficacy and low toxicity in a broad array of oncology indications.

Recently, Henlius' self-developed anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab, trade name: Hetronifly^® in Europe) has secured approvals in Singapore and Malaysia through its local license holder, KGbio (a subsidiary of PT Kalbe Farma Tbk.), under the trade name Zerpidio^® for the treatment of extensive-stage small cell lung cancer (ES-SCLC). This marks another significant expansion in Southeast Asia following earlier approvals in Indonesia, Cambodia, and Thailand. Under the agreement, serplulimab’s commercialization in Southeast Asia is managed by KGbio, which holds exclusive rights to develop and commercialize the drug for certain indications and therapies across 10 ASEAN countries.

(11 June 2025) Fosun International Limited (HKEX stock code: 00656) was recently notified by the renowned British finance magazine, Global Banking and Finance Review, that it has received three awards: “ESG & Sustainability Awards – Best Sustainable Development Company Asia 2025”, “CSR Awards – Best CSR Company Asia 2025”, and “Brand of the Year Awards – Holding Group Brand of the Year Asia 2025”. These accolades underscore the market’s recognition of Fosun’s exceptional performance in ESG strategy, corporate governance, social responsibility, environmental protection, information disclosure, and stakeholder engagement.

On June 5, Henlius (2696.HK) participated in the 2025 Jefferies Global Healthcare Conference. As one of the most influential investment summits in the global life sciences industry, the event brought together over 3,000 leading executives, institutional investors, private equity investors and venture capitals to discuss current global trends and opportunities across the healthcare sector.

The updated data of efficacy and safety of Luvometinib (FCN-159), a self-developed innovative drug by Fosun Pharma, in pediatric participants with neurofibromatosis type 1 from a phase 2 study was presented in the American Society of Clinical Oncology (ASCO) Annual Meeting on May 22, 2025.

Shanghai, China, June, 3, 2025 – Shanghai Henlius Biotech, Inc. (2696. HK) announced the first release of results from the phase 1 clinical trial of HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), for the treatment of advanced or metastatic solid tumors at the 2025 ASCO Annual Meeting. The leading principal investigator of this study is Jie Wang from the Cancer Hospital Chinese Academy of Medical Sciences. Leveraging on the precise molecular design and multiple innovative mechanisms, HLX43 has demonstrated superior anti-tumor activity with a manageable safety profile in patients with advanced/metastatic solid tumors. Particularly, encouraging preliminary efficacy was observed in non-small cell lung cancer (NSCLC) and thymic squamous cell carcinoma (TSCC) patients, demonstrating best-in-class potential for clinical development. At present, no PD-L1 targeting ADC has been approved for marketing globally. HLX43 may thus benefit more patients with advanced or metastatic solid tumors by providing a novel treatment option for those who are unresponsive or have developed resistance to PD-1/PD-L1-targeted therapies.

On June 2, 2025, Henlius (2696.HK) announced that the latest research results of novel anti-HER2 monoclonal antibody (mAb) HLX22 were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These included updated efficacy and safety data with over two years of follow-up from the phase 2 clinical study (HLX22-GC-201) evaluating HLX22 in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive advanced gastric cancer, as well as the debut of the study design for the international multicentre phase 3 clinical trial (HLX22-GC-301), which features a head-to-head comparison with the first-line standard of care therapy (trastuzumab + chemotherapy ± pembrolizumab).